A retrospective real world multicenter study assessing the efficacy and safety of 8-week GLE/PIB in chronic hepatitis C patients depending on liver fibrosis and genotype
Latest Information Update: 18 Nov 2020
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Nov 2020 New trial record
- 10 Nov 2020 Results published in the Journal of Gastroenterology and Hepatology